Nilotinib-Induced Thromboembolic Events: A Case Study

Zahra Kmira *

Department of Clinical Hematology, Farhat Hached University Hospital, Sousse, Tunisia.

Ben Yahya Noura

Department of Clinical Hematology, Farhat Hached University Hospital, Sousse, Tunisia.

Guermazi Monia

Department of Clinical Hematology, Farhat Hached University Hospital, Sousse, Tunisia.

Fathallah Neila

Department of Pharmacology, Farhat Hached University Hospital, Sousse, Tunisia.

Atig Amira

Department of Internal Medicine, Farhat Hached University Hospital, Sousse, Tunisia.

Chembah Wafa

Department of Clinical Hematology, Farhat Hached University Hospital, Sousse, Tunisia.

Thabet Maissa

Department of Internal Medicine, Farhat Hached University Hospital, Sousse, Tunisia.

Zaier Monia

Department of Clinical Hematology, Farhat Hached University Hospital, Sousse, Tunisia.

Ben Youssef Yosra

Department of Clinical Hematology, Farhat Hached University Hospital, Sousse, Tunisia.

Haifa Regaieg

Department of Clinical Hematology, Farhat Hached University Hospital, Sousse, Tunisia.

Khelif Abderrahim

Department of Clinical Hematology, Farhat Hached University Hospital, Sousse, Tunisia.

*Author to whom correspondence should be addressed.


Abstract

Nilotinib has significantly improved the treatment of chronic myeloid leukemia (CML) by offering enhanced efficacy and tolerability. However, studies have revealed a concerning link between nilotinib and an increased risk of thromboembolic events, even compared to other tyrosine kinase inhibitors (TKIs). This case report presents a forty-four-year-old male with CML treated with nilotinib, who developed dyslipidemia and multiple arterial occlusive events, including renal thrombosis and carotid artery atheroma. The potential mechanisms underlying nilotinib-induced thromboembolic events are endothelial cell dysfunction, altered lipid metabolism, and pro-inflammatory and prothrombotic effects. Identifying preexisting cardiovascular risks and implementing proactive measures may aid in reducing the occurrence of thromboembolic events in high-risk patients treated with nilotinib.

Keywords: Nilotinib, thromboembolic events, outcome


How to Cite

Kmira, Zahra, Ben Yahya Noura, Guermazi Monia, Fathallah Neila, Atig Amira, Chembah Wafa, Thabet Maissa, Zaier Monia, Ben Youssef Yosra, Haifa Regaieg, and Khelif Abderrahim. 2025. “Nilotinib-Induced Thromboembolic Events: A Case Study”. Journal of Advances in Biology & Biotechnology 28 (1):596-602. https://doi.org/10.9734/jabb/2025/v28i11912.